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Abstract. Our aim was to estimate the pooled risk of current and former smoking for Parkinson’s disease (PD).We have reviewed
all observational studies that evaluated the association between PD risk and smoking habit. Twenty six studies were identified:
21 case-control, 4 cohort and 1 cross-sectional. The cross-sectional study did not compare former with never smokers. These
studies were carried out between 1968 and 2000.
There was an obvious protective effect of current smoking in the pooled estimate [risk estimate 0.37 (95% confidence interval
0.33 to 0.41)]. Former versus never smokers had pooled risk estimate of 0.84 (95% confidence interval 0.76 to 0.92). Current and
former smoking do not, therefore, exert the same protective effect against PD so that it is unnecessary to postulate a biological
mechanism through which smoking protects against PD. The results show that the reverse direction of causation is a more
probable explanation, i.e. movement disorders of PD protect against smoking. Another explanation is that failure to develop
strong smoking habits in early adult life might be a prodromal symptom of the disease and could perhaps be its first clinical
manifestation.
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1. Introduction
Numerous studies over the past several decades have
demonstrated an inverse association between cigarette
smoking and Parkinson’s disease (PD), although clear
explanations are lacking. The intriguing association
was generally supported by many case-control and
prospective cohort studies. However, recent case-
control studies did not identify a clear protective ef-
fect and were in favor of the association reported in
the other studies possibly being artefactual [8,11,32].
We also noted when reviewing studies supporting the
inverse association that they showed quite a wide range
of risk estimates.
Hypotheses concerning the relationship of smok-
ing to lowered risk of PD, apart from those propos-
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ing real biological mechanisms to explain how smok-
ing protects against PD, are various and independent.
Previously advanced hypotheses have included: 1)
selective mortality among smokers at early ages be-
cause of smoking’s side effects and/or the selective ge-
netic predisposition of smokers, which tends to lead to
their early death [11,32]; 2) confounding, common life
styles associated with smoking, such as coffee drink-
ing, which was recently suggested to be associated with
lower incidence of PD [8,32]; 3) reverse causation, ac-
cording to which PD is associated with incomplete mo-
tor control that makes it less likely that PD patients will
smoke or continue to smoke because of the motoric
challenge posed when compared to people with normal
levels of motor control [8,11,32]; 4) PD-associated per-
sonality differences, according to which persons pre-
destined to get PD tend to be more passive, more intro-
spective, more self-controlled, less likely to take risks
and so tend to choose not to smoke [11].
The first two hypotheses could be excluded based on
the results of cohort studies that adjusted their results
ISSN 0953-4180/04/$17.00  2004 – IOS Press and the authors. All rights reserved
66 M.F. Allam et al. / Parkinson’s disease protects against smoking?
for age and possible confounding factors like coffee
intake. Meanwhile, the latter two possibilities were not
investigated sufficiently till now.
Comparing the risk of PD in current and former ver-
sus never smokers provides a fuller examination of the
real association [21]. If current and former smoking
exert the same protective effect, then it is acceptable
to argue that smoking truly provides protection against
developing PD. If, however, current smoking demon-
strates a greater protective effect than former smoking,
then a cause-and-effect bias is the explanation.
The aim of the present study was to estimate the
pooled risk of current and former smoking for PD.
2. Materials and methods
2.1. Literature review
Published observational studies on PD and cigarette
smoking were identified through a comprehensive
MEDLINE search (from 1966 to January 2001) and
PsycLIT (from 1887 to January 2001) using a vari-
ety of Medical Subjects Headings and free text words:
(SMOKING OR TOBACCO OR CIGARETTE) AND
(PARKINSON OR PD) AND (CASE-CONTROL
OR CASE-REFERENT OR RETROSPECTIVE OR
COHORT OR FOLLOW-UP OR INCIDENT OR
PROSPECTIVE OR EPIDEMIOLOGY). We con-
ducted additional searches of Current Contents, Best
Evidence, Nisc Mexico Biblioline, previous reviews,
examination of cited reference sources and personal
contact and discussion with several investigators expert
in the field. Published case reports, studies evaluating
other smoking habits, or smoking habits not stratified
as current and former smokers were excluded. When
two or more papers were based on an identical study,
the paper that principally investigated the relationship
between PD and smoking was used. We considered
studies in all languages and no attempts were made to
locate any unpublished study.
2.2. Data extraction
We identified 26 published studies on the basis of our
inclusion criteria [1–6,9,10,12,14,17–19,21,23,25,28–
30,33,36,38,40,41,44,45]. A copy of each paper iden-
tified was obtained, and relevant data were abstracted
by the first author (M.F.A.) for a quantitative overview.
The type of risk estimate (i.e. relative risk, standard-
ized mortality rate, odds ratio or prevalence odds ratio)
and the country where the study was carried out were
also ascertained. In case of discrepancies or when the
information presented in a study was unclear, abstrac-
tion by a second reviewer (R.F.N.) was sought to re-
solve the discrepancy. All the included studies, except
one, reported associations for current and former smok-
ers. The remaining study reported only comparisons
for current smokers [21].
2.3. Statistical methods for meta-analysis
Data were abstracted from every study in the form of
a risk estimate and its 95% confidence interval. When
a risk estimate and its 95% confidence interval were
not available from the article, we calculated unadjusted
values from the published data of the article, using the
Epi Info 6 computer program version 6.04d [13].
Risk estimate refers to relative risk or odds ratio. Rel-
ative risk compares the probability of an outcome (PD)
among individuals who have been exposed to a given
risk factor (smoking) to the probability of that out-
come (control) among individuals who have not been
exposed (never smoker). It means that the disease is
relative risk times more likely to occur among those
exposed to the risk factor than among those with no
such exposure. Relative risk can be calculated only in
a cohort or experimental study, meanwhile odds ratio
can be calculated only in a case-control study [39].
Pooled risk estimate was obtained by weighing each
study by the inverse variance of the effect measure on
a logarithmic scale. This approach to pool the results
assumes that the study populations being compared are
similar and hence corresponds to a fixed effect analysis.
The validity of pooling the risk estimates was tested
(test of homogeneity) using a Chi square test [20].
A violation of this test implies that the studies being
grouped differ from one another. In the presence of
significant heterogeneity of the effect measure among
studies being compared, we performed a random effect
analysis that was based on the method described by
DerSimonian and Laird (1986) [37]. The random effect
analysis accounts for the interstudy variation. Because
the test of homogeneity has low power, we reported
the figures of the random effect analysis even with the
absence of significant heterogeneity.
All statistical analysis for pooling the studies were
performed on the STATA Statistical Software, release
7.0 (StataCorp. 2001).
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Table 1
Studies evaluating the risk of PD in current versus never smokers
Authors Year of publication Study type Risk estimate 95% confidence interval
Giroud-Benitez 2000 CS 0.12 0.08–0.19
Benedetti 2000 CC 0.62 0.38–1.01
Kuopio 1999 CC 0.50 0.20–1.24
Nelson 1999 CC 0.22 0.12–0.40
Fall 1999 CC 0.17 0.06–0.43
Chan 1998 CC 0.52 0.26–1.01
Hellenbrand 1997 CC 0.26 0.18–0.39
de Rijk 1997 C 0.50 0.18–1.43
Ben-Shlomo 1996 CC 0.36 0.20–0.67
Martyn 1995 CC 0.49 0.26–0.91
Doll 1994 C 0.75 0.38–1.46
Grandinetti 1994 C 0.24 0.12–0.48
Mayeux 1994 CC 0.20 0.10–0.50
Sasco 1990 CC 0.51 0.23–1.13
Zayed 1990 CC 0.10 0.00–0.83
Hofman 1989 CC 0.70 0.40–1.40
Rajput 1987 CC 0.46 0.23–0.92
Granerus 1987 CS 0.77 0.33–1.81
Cazzato 1985 CC 0.12 0.05–0.31
Ogawa 1984 CC 0.58 0.38–0.87
Godwin-Austen 1982 CC 0.48 0.32–0.71
Marttila 1980 CC 0.38 0.23–0.62
Rogot 1980 C 0.32 0.24–0.43
Kessler 1972 CC 0.42 0.25–0.70
Kessler 1971 CC 0.46 0.32–0.66
Nefzger 1968 CC 0.31 0.18–0.55
Pooled risk estimate 0.37 0.33–0.41
CC: Case–control study.
CS: Cross-sectional study.
C: Cohort study.
3. Results
We localized 63 observational studies that evaluated
the association between PD risk and cigarette smoking.
Only 26 studies compared PD rates in current and never
smokers, and of these studies four were prospective
studies. The 26 studies included one cross-sectional
study that did not compare former with never smokers.
Most of the studies were published in English and only
five studies were published in French, Spanish, Italian,
Swedish and Japanese. The studies represented dif-
ferent populations of all continents except Africa and
Australia. The results of these studies were published
between 1968 and 2000.
3.1. The risk of PD in current versus never smokers
The pooled risk estimate of current versus never
smokers demonstrated a one-third risk of PD in current
smokers [risk estimate 0.37 (95% confidence interval
0.33 to 0.41)]. The chi-square value of the homogene-
ity test was 72.6 with p value <0.001, denoting hetero-
geneity across the pooled twenty-six studies (Table 1).
Pooled analysis applying the random effect model was
0.37 (95% confidence interval 0.31 to 0.45).
3.2. The risk of PD in former versus never smokers
Former versus never smokers had pooled risk esti-
mate of 0.84 with 95% confidence interval 0.76 to 0.92.
The homogeneity test of the twenty-five studies had a
p value of 0.24, indicating homogenous results of the
pooled studies (Table 2). Pooled analysis applying the
random effect model was 0.83 (95% confidence interval
0.75 to 0.92).
4. Discussion
Perhaps one of the most important questions posed
by the neurobiology of aging concern the pathogenic
mechanisms in PD. Although the aetiology of PD is still
unknown, increasing evidence supports the hypothesis
that environmental factors may contribute to its occur-
rence. Our meta-analysis was intended to check the
role of an environmental factor, smoking habit, known
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Table 2
Studies evaluating the risk of PD in former versus never smokers
Authors Year of publication Study type Risk estimate 95% confidence interval
Benedetti 2000 CC 1.14 0.41–3.15
Kuopio 1999 CC 1.08 0.66–1.76
Nelson 1999 CC 0.99 0.75–1.29
Fall 1999 CC 0.82 0.44–1.51
Chan 1998 CC 0.91 0.62–1.33
Hellenbrand 1997 CC 0.92 0.69–1.23
de Rijk 1997 C 0.26 0.09–0.78
Ben-Shlomo 1996 CC 0.73 0.47–1.14
Martyn 1995 CC 0.61 0.40–0.94
Doll 1994 C 1.10 0.60–2.02
Grandinetti 1994 C 0.50 0.27–0.93
Mayeux 1994 CC 0.90 0.50–1.60
Sasco 1990 CC 0.77 0.35–1.69
Zayed 1990 CC 1.75 0.74–4.18
Hofman 1989 CC 0.50 0.30–1.00
Rajput 1987 CC 1.10 0.60–2.03
Granerus 1987 CS 0.99 0.42–2.36
Cazzato 1985 CC 1.02 0.51–2.04
Ogawa 1984 CC 0.74 0.30–1.67
Godwin-Austen 1982 CC 0.80 0.56–1.15
Marttila 1980 CC 1.04 0.73–1.49
Rogot 1980 C 0.70 0.52–0.94
Kessler 1972 CC 0.54 0.33–0.88
Kessler 1971 CC 0.92 0.67–1.26
Nefzger 1968 CC 0.68 0.37–1.21
Pooled risk estimate 0.84 0.76–0.92
CC: Case–control study.
CS: Cross-sectional study.
C: Cohort study.
for its harmful effects generally, but offering a possible
protection against PD, mediated by biological mecha-
nism.
Before reaching conclusions based on the present
results, it is necessary to consider a number of poten-
tial objections to our procedures. Methodological con-
cerns include limitations in the quality of the primary
data, as the usefulness of meta-analysis is largely de-
pendent on the quality of the studies used. Combining
randomized controlled trials provides more evidence,
but is clearly impossible in studying the aetiology of a
chronic disease as in our case [43].
Reviewing the literature, there have been four sys-
tematic and narrative reviews that investigated the
smoking habit/PD association, but our comprehensive
search has identified more studies than previous re-
views [11,15,24,32]. These reviews missed last follow-
up or even complete studies not cited by MEDLINE.
The results of Rogot and Murray (1980) of 16 years
follow-up on US Male Veterans have never been in-
cluded before [12]. The Rotterdam, a population-based
cohort study, was not identified by other reviewers.
This study reported results of incident idiopathic PD
cases after well-established criteria for case identifica-
tion [28]. Recently, two review studies [24,32], one of
them a quantitative review [32], reported results of 20
years’ observations on Male British Doctors, although
40 years’ observations were published in 1994 [38].
Also, and of note, quantitative reviews are usually re-
stricted to studies published in English. This raises con-
cern regarding the external validity of their results [26].
Our meta-analysis has included studies published in
six languages. The study of Zayed et al. (1990), pub-
lished in French, has never been included before in
other quantitative review [23].
The pooled studies in our meta-analysis were well
designed and carefully executed. However, they varied
with regard to study design, size, quality of diagnosis
and measure of exposure. We think that pooling of this
heterogeneous set of studies adds useful information to
that provided by individual studies of the highest qual-
ity, such as the Male British Doctors or the Honolulu
Heart Study.
Our meta-analysis showed that there was an obvious
protective effect of current smoking in the pooled esti-
mate [risk estimate 0.37 (95% confidence interval 0.33
to 0.41)]. This means that current smoking is inversely
associated with the risk of PD, in concordance with the
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results of several previous studies [11,32]. However,
the homogeneity test was very highly significant, which
proves the heterogeneity of the results of pooled stud-
ies. The heterogeneous and contradictory results could
not describe a real biological protective mechanism and
calls for a consideration of possible biases.
Pooled risk estimate between former smoking and
PD was of 0.84 (95% confidence interval 0.76 to 0.92).
The homogeneity test had a non-significant p value,
denoting homogeneity of the pooled results. These
consistent results should be considered more conclusive
and precise.
It is of note that the four cohort studies included
have demonstrated inconsistent results in the sub-
group analysis. Meanwhile, US Veterans Study, Male
British Doctors Study and Honolulu Heart study re-
sults showed that former smokers are at intermediate
risk between current and never smokers [1,12,38]. The
Rotterdam Study showed a higher risk of idiopathic PD
among current smokers [28]. This contradictory result
was based on only 34 incident cases during a three-year
follow-up. The Rotterdam study is ongoing since 1990
and future analysis with new incident cases should help
elucidate this contradictory result.
Also of note, the retrospective studies that evaluated
the risk of PD in current versus never smokers have not
demonstrated a clear protective effect with pooled odds
ratio of 0.87 (95% CI 0.79 to 0.96). In addition, many
retrospective studies have shown a clear inverse associ-
ation in comparisons of current versus never smokers.
The same studies in comparisons of former with never
smokers reported odds ratios with 95% confidence in-
tervals that overlapped unity, and so were inconsistent
with the protective effect hypothesis [2,14,17,18,23,25,
30,33,36,40,41,44,45].
PD is an acquired disease, associated with toxic-
environmental exposure 20 to 40 years before the ap-
pearance of the first symptoms [16,22]. Evaluation
of the relation between tobacco smoking and PD risk,
comparing former smokers with non-smokers, should
be more appropriate than any other comparison. The
low frequency of current smokers among PD patients,
in turn, cannot only be attributed to the possible pro-
tective effect of tobacco smoking. Systematic biases,
like reverse causation and PD-associated personality
difference, could be the explanation [11,28].
Our meta-analysis shows that the reverse causation
bias is a possible explanation since the pooled analysis
of former smokers had a relative risk much closer to
unity, and it is more probable that movement disorders
of PD protect against smoking.
It is logical that patients with neurological disease
associated with movement disorders give up smoking.
Patients with PD may stop smoking after the onset of
the disease because of physiological reasons or psycho-
logical dislike, and this affects the validity of the results
of the case-control studies [11,15]. By extension, the
first symptoms of PD appear many years before its di-
agnosis, with loss of fine movements, and these persons
might choose not to smoke.
Another explanation is that failure to develop strong
smoking habits in early adult life might be a prodromal
symptom of the disease; it could be the first clinical
manifestation [11]. The lower incidence of alcoholism
in PD, noted since 1966, suggests an early behavioral
expression of the disease [31]. If so, there could be
something different about PD patients many years be-
fore the onset of extrapyramidal symptoms, probably
as early as late adolescence or early adult years, when
smoking and drinking habits tend to be acquired [11,
16,22].
It has been suggested that subjects showing novelty-
seeking behavior and addiction have higher dopamine
levels [27,31]. Recent results from the Rotterdam study
show that cigarette smoking, alcohol drinking and cof-
fee consumption have a reduced risk of PD, and the
trend towards lower risks is associated with higher ex-
posures. Since three different addictive agents show
this same trend, the authors explained their findings
by the higher endogenous dopamine levels in subjects
showing novelty-seeking behavior and addiction [35].
In concordance with our hypothesis, controlled clin-
ical trials have failed to demonstrate a beneficial effect
of nicotine consumption in PD. Nicotine chewing gum
and transdermal nicotine patches have been used as an
add-on treatment for the symptoms of PD. However,
both forms of nicotine administration had no significant
effects [7,34].
In conclusion, stratification of the smoking habit,
current and former smoking, is a promising explana-
tion for the controversial association between PD and
tobacco smoking, and calls for further studies.
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